SI1666033T1 - Preprečevanje in zdravljenje s pomankanjem androgena inducirane osteoporoze - Google Patents

Preprečevanje in zdravljenje s pomankanjem androgena inducirane osteoporoze

Info

Publication number: SI1666033T1
Authority: SI; Slovenia
Prior art keywords: androgen; deprivation induced; prevention; treatment; induced osteoporosis
Prior art date: 2001-11-29

Application number

SI200230801T

Other languages

English (en)

Inventor

Mitchell S Steiner

Sharan Raghow

Karen A Veverka

Original Assignee

Gtx Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-11-29

Filing date

2002-11-27

Publication date

2009-06-30

2002-11-27 Application filed by Gtx Inc filed Critical Gtx Inc

2009-06-30 Publication of SI1666033T1 publication Critical patent/SI1666033T1/sl

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/01—Hydrocarbons
- A61K31/015—Hydrocarbons carbocyclic
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/02—Halogenated hydrocarbons
- A61K31/025—Halogenated hydrocarbons carbocyclic
- A61K31/03—Halogenated hydrocarbons carbocyclic aromatic
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Physical Education & Sports Medicine (AREA)
Endocrinology (AREA)
Diabetes (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Reproductive Health (AREA)
Gynecology & Obstetrics (AREA)
Urology & Nephrology (AREA)
Emergency Medicine (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Steroid Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

SI200230801T 2001-11-29 2002-11-27 Preprečevanje in zdravljenje s pomankanjem androgena inducirane osteoporoze SI1666033T1 (sl)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US33373401P	2001-11-29	2001-11-29
EP05028100A EP1666033B1 (en)	2001-11-29	2002-11-27	Prevention and treatment of androgen-deprivation induced osteoporosis

Publications (1)

Publication Number	Publication Date
SI1666033T1 true SI1666033T1 (sl)	2009-06-30

Family

ID=23304031

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
SI200230801T SI1666033T1 (sl)	2001-11-29	2002-11-27	Preprečevanje in zdravljenje s pomankanjem androgena inducirane osteoporoze
SI200230705T SI1460969T1 (sl)	2001-11-29	2002-11-27	Preprečevanje in zdravljenje s pomanjkanjem androgena inducirane osteoporoze

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
SI200230705T SI1460969T1 (sl)	2001-11-29	2002-11-27	Preprečevanje in zdravljenje s pomanjkanjem androgena inducirane osteoporoze

Country Status (22)

Country	Link
US (1)	US6899888B2 (sl)
EP (5)	EP1460969B1 (sl)
JP (2)	JP2005515988A (sl)
KR (1)	KR100658110B1 (sl)
CN (2)	CN1679956A (sl)
AT (2)	ATE418972T1 (sl)
AU (2)	AU2002356928B2 (sl)
BR (1)	BR0214801A (sl)
CA (2)	CA2468719C (sl)
CY (2)	CY1108174T1 (sl)
DE (2)	DE60230687D1 (sl)
DK (2)	DK1666033T3 (sl)
EA (1)	EA200400744A1 (sl)
ES (2)	ES2319785T3 (sl)
GE (1)	GEP20094841B (sl)
HR (1)	HRP20040547A2 (sl)
IL (2)	IL162144A0 (sl)
MX (1)	MXPA04005112A (sl)
PT (2)	PT1666033E (sl)
SI (2)	SI1666033T1 (sl)
TW (1)	TWI315987B (sl)
WO (1)	WO2003047504A2 (sl)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20040186185A1 (en) *	1998-05-07	2004-09-23	Steiner Mitchell S.	Method for treatment and chemoprevention of prostate cancer
US20040092602A1 (en) *	1998-05-07	2004-05-13	Steiner Mitchell S.	Method for treatment and chemoprevention of prostate cancer
US7645898B2 (en) *	2000-08-24	2010-01-12	University Of Tennessee Research Foundation	Selective androgen receptor modulators and method of use thereof
US7919647B2 (en)	2000-08-24	2011-04-05	University Of Tennessee Research Foundation	Selective androgen receptor modulators and methods of use thereof
US7855229B2 (en) *	2000-08-24	2010-12-21	University Of Tennessee Research Foundation	Treating wasting disorders with selective androgen receptor modulators
US7622503B2 (en) *	2000-08-24	2009-11-24	University Of Tennessee Research Foundation	Selective androgen receptor modulators and methods of use thereof
US7524866B2 (en) *	2001-11-29	2009-04-28	Gtx, Inc.	Prevention and treatment of androgen—deprivation induced osteoporosis
US20080249183A1 (en) *	2001-11-29	2008-10-09	Steiner Mitchell S	Treatment of androgen-deprivation induced osteoporosis
US20070197664A1 (en) *	2001-11-29	2007-08-23	Steiner Mitchell S	Prevention and treatment of androgen-deprivation induced osteoporosis
US20060269611A1 (en) *	2001-11-29	2006-11-30	Steiner Mitchell S	Prevention and treatment of androgen-deprivation induced osteoporosis
US20040214898A1 (en) *	2001-11-29	2004-10-28	Steiner Mitchell S.	Methods for treating hot flashes
US20050080143A1 (en) *	2001-11-29	2005-04-14	Steiner Mitchell S.	Treatment of androgen-deprivation induced osteoporosis
US8853266B2 (en) *	2001-12-06	2014-10-07	University Of Tennessee Research Foundation	Selective androgen receptor modulators for treating diabetes
US20070161608A1 (en) *	2001-12-06	2007-07-12	Dalton James T	Selective androgen receptor modulators for treating muscle wasting
US7332525B2 (en) *	2003-01-17	2008-02-19	Castle Erik P	Method of treatment of prostate cancer and composition for treatment thereof
US9884038B2 (en)	2004-06-07	2018-02-06	University Of Tennessee Research Foundation	Selective androgen receptor modulator and methods of use thereof
US9889110B2 (en)	2004-06-07	2018-02-13	University Of Tennessee Research Foundation	Selective androgen receptor modulator for treating hormone-related conditions
US20110237664A1 (en) *	2004-06-07	2011-09-29	Dalton James T	Selective androgen receptor modulators for treating diabetes
US20060019989A1 (en) *	2004-07-21	2006-01-26	Steiner Mitchell S	Compositions comprising 5-alpha reductase inhibitors and SERMs and methods of use thereof
BRPI0514701A (pt) *	2004-09-03	2008-06-24	Hormos Medical Ltd	uso de um modulador do receptor de estrogênio seletivo, ou um isÈmero, mistura de isÈmero, metabólito ou um sal farmaceuticamente aceitável do mesmo
US20060270641A1 (en) *	2005-05-31	2006-11-30	Steiner Mitchell S	Method for chemoprevention of prostate cancer
BRPI0618510A2 (pt) *	2005-11-09	2011-09-06	Hormos Medical Ltd	formulação medicamentosa lìquida ou semi-sólida
EP2455362A1 (en) *	2005-11-28	2012-05-23	GTX, Inc.	Nuclear receptor binding agents
US8546451B2 (en)	2005-11-28	2013-10-01	Gtx, Inc.	Estrogen receptor ligands and methods of use thereof
US8637706B2 (en)	2005-11-28	2014-01-28	Gtx, Inc.	Nuclear receptor binding agents
US9409856B2 (en)	2005-11-28	2016-08-09	Gtx, Inc.	Estrogen receptor ligands and methods of use thereof
US8158828B2 (en) *	2005-11-28	2012-04-17	Gtx, Inc.	Nuclear receptor binding agents
US7504530B2 (en)	2007-02-14	2009-03-17	Hormos Medical Ltd.	Methods for the preparation of fispemifene from ospemifene
KR101510646B1 (ko)	2007-02-14	2015-04-10	호르모스 메디칼 리미티드	치료적으로 유용한 트리페닐부텐 유도체의 제조 방법
US7968603B2 (en)	2007-09-11	2011-06-28	University Of Tennessee Research Foundation	Solid forms of selective androgen receptor modulators
PL2222636T3 (pl)	2007-12-21	2014-04-30	Ligand Pharm Inc	Selektywne modulatory receptorów androgenowych (SARM) i ich zastosowania
US9624161B2 (en)	2009-02-23	2017-04-18	Gtx, Inc.	Estrogen receptor ligands and methods of use thereof
US9427418B2 (en)	2009-02-23	2016-08-30	Gtx, Inc.	Estrogen receptor ligands and methods of use thereof
US10258596B2 (en)	2012-07-13	2019-04-16	Gtx, Inc.	Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
US9744149B2 (en)	2012-07-13	2017-08-29	Gtx, Inc.	Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US9622992B2 (en)	2012-07-13	2017-04-18	Gtx, Inc.	Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US10314807B2 (en)	2012-07-13	2019-06-11	Gtx, Inc.	Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
US10987334B2 (en)	2012-07-13	2021-04-27	University Of Tennessee Research Foundation	Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs)
DK2872482T3 (da)	2012-07-13	2020-09-21	Oncternal Therapeutics Inc	En fremgangsmåde til behandling af brystkræft med selektiv androgenreceptormodulator (sarm)
US9969683B2 (en)	2012-07-13	2018-05-15	Gtx, Inc.	Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS)
US9321712B2 (en)	2012-10-19	2016-04-26	Fermion Oy	Process for the preparation of ospemifene
EP3613418A1 (en)	2014-01-17	2020-02-26	Ligand Pharmaceuticals, Inc.	Methods and compositions for modulating hormone levels
KR20170040797A (ko) *	2014-07-24	2017-04-13	아스펜 파크 파마슈티컬스 인코포레이티드	시스-클로미펜을 이용하여 안드로겐 박탈 요법 유발된 일과성 열감 및 골 소실을 치료하는 방법
CN114096522A (zh)	2019-04-19	2022-02-25	利亘制药公司	化合物的晶型和制备化合物的晶型的方法

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2464203A (en)	1943-05-21	1949-03-15	Boots Pure Drug Co Ltd	Manufacture of dienoestrol
US2465505A (en)	1944-12-05	1949-03-29	Hoffmann La Roche	Process for the manufacture of 3, 4-di-(p-hydroxy-phenyl)-hexadiene-2, 4
US2914562A (en)	1957-08-06	1959-11-24	Wm S Merrell Co	Amine derivatives of triphenylethanol
GB2126576B (en)	1982-06-25	1985-06-19	Farmos Group Limited	Alkane and alkene derivatives
US5491173A (en)	1982-06-25	1996-02-13	Orion-Yhtyma Oy	Tri-phenyl alkene derivatives and their preparation and use
US4729999A (en) *	1984-10-12	1988-03-08	Bcm Technologies	Antiestrogen therapy for symptoms of estrogen deficiency
JP3350048B2 (ja) *	1989-07-07	2002-11-25	アンドルシェルシュ・インコーポレイテッド	アンドロゲン関連疾患の治療方法
GB9126209D0 (en)	1991-12-10	1992-02-12	Orion Yhtymae Oy	Drug formulations for parenteral use
GB9207437D0 (en)	1992-04-03	1992-05-20	Orion Yhtymae Oy	Topical administration of toremifene and its metabolites
US5468488A (en) *	1993-06-24	1995-11-21	Wahi; Ashok L.	Electrostatically charged nasal application product and method
TW303299B (sl) *	1993-07-22	1997-04-21	Lilly Co Eli
US5552412A (en) *	1995-01-09	1996-09-03	Pfizer Inc	5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis
DE19526146A1 (de) *	1995-07-07	1997-01-09	Schering Ag	Triphenylethylene, Verfahren zu deren Herstellung, diese Triphenylethylene enthaltene pharmazeutische Präparate sowie deren Verwendung zur Herstellung von Arzneimitteln
IL120262A (en) *	1996-02-28	2001-01-28	Pfizer	Droloxifene and derivatives thereof for use in increasing serum testosterone levels
US5859045A (en) *	1996-05-08	1999-01-12	Novo Nordisk A/S Novo Alle	Crystalline -! 3R 4R-trans-7 methoxy 2,2-dimethyl1-3-phenyl 1-4 4-12 pyrrolidin-1 -Y1!ethoxyl 1!chromane hydrogen fumarate
US6413534B1 (en)	1998-05-07	2002-07-02	The University Of Tennessee Research Corporation	Method for chemoprevention of prostate cancer
US6632447B1 (en)	1998-05-07	2003-10-14	The University Of Tennessee Research Corporation	Method for chemoprevention of prostate cancer
DE69922131T2 (de)	1998-05-07	2005-11-24	The University Of Tennessee Research Corp., Knoxville	Medikament zur behandlung intraepithelialer prostataneoplasie
US6413533B1 (en)	1998-05-07	2002-07-02	The University Of Tennessee Research Corporation	Method for chemoprevention of prostate cancer
JP2002518328A (ja) *	1998-06-16	2002-06-25	ファイザー・プロダクツ・インク	筋骨格虚弱の治療用の（選択的）エストロゲン受容体モジュレーター（ｓｅｒｍ）および成長ホルモン分泌促進薬（ｇｈｓ）の治療的組合せ
EP1004306A3 (en) *	1998-08-06	2000-06-07	Pfizer Products Inc.	Estrogen agonists/antagonists
CA2339368A1 (en) *	1998-08-07	2000-02-17	Endorecherche, Inc.	Inhibitors of type 3 3.alpha.-hydroxysteroid dehydrogenase
DE69929345T2 (de) *	1998-08-07	2006-09-21	Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville	Substituierte isoxal-derivate als östrogenrezeptormodulatoren
AU5181200A (en) *	1999-06-04	2000-12-28	General Hospital Corporation, The	Pharmaceutical formulations for treating postmenopausal and perimenopausal women, and their use
CN1281598C (zh) *	1999-12-30	2006-10-25	信号药品公司	调节雌激素受体的化合物和方法
GB0012291D0 (en) *	2000-05-23	2000-07-12	Astrazeneca Ab	Pharmaceutical combination
EP1324754A1 (en) *	2000-07-05	2003-07-09	AstraZeneca AB	Pharmaceutical combination of an anti-androgen and tamoxifen for providing an anti-androgenic effect and aromatase inhibition

2002
- 2002-11-27 IL IL16214402A patent/IL162144A0/xx unknown
- 2002-11-27 KR KR1020047008234A patent/KR100658110B1/ko not_active Expired - Fee Related
- 2002-11-27 AT AT05028100T patent/ATE418972T1/de active
- 2002-11-27 AT AT02804417T patent/ATE394099T1/de active
- 2002-11-27 DK DK05028100T patent/DK1666033T3/da active
- 2002-11-27 EP EP02804417A patent/EP1460969B1/en not_active Expired - Lifetime
- 2002-11-27 US US10/305,363 patent/US6899888B2/en not_active Expired - Fee Related
- 2002-11-27 EA EA200400744A patent/EA200400744A1/ru unknown
- 2002-11-27 AU AU2002356928A patent/AU2002356928B2/en not_active Ceased
- 2002-11-27 CN CNA2005100638704A patent/CN1679956A/zh active Pending
- 2002-11-27 MX MXPA04005112A patent/MXPA04005112A/es active IP Right Grant
- 2002-11-27 DK DK02804417T patent/DK1460969T3/da active
- 2002-11-27 PT PT05028100T patent/PT1666033E/pt unknown
- 2002-11-27 PT PT02804417T patent/PT1460969E/pt unknown
- 2002-11-27 ES ES05028100T patent/ES2319785T3/es not_active Expired - Lifetime
- 2002-11-27 GE GEAP20028274A patent/GEP20094841B/en unknown
- 2002-11-27 CA CA2468719A patent/CA2468719C/en not_active Expired - Fee Related
- 2002-11-27 ES ES02804417T patent/ES2305350T3/es not_active Expired - Lifetime
- 2002-11-27 SI SI200230801T patent/SI1666033T1/sl unknown
- 2002-11-27 BR BR0214801-3A patent/BR0214801A/pt not_active Application Discontinuation
- 2002-11-27 EP EP05028100A patent/EP1666033B1/en not_active Expired - Lifetime
- 2002-11-27 CN CNB028276930A patent/CN100548283C/zh not_active Expired - Fee Related
- 2002-11-27 CA CA002537913A patent/CA2537913A1/en not_active Abandoned
- 2002-11-27 EP EP07111247A patent/EP1862165A3/en not_active Withdrawn
- 2002-11-27 EP EP08172485A patent/EP2098247A3/en not_active Withdrawn
- 2002-11-27 DE DE60230687T patent/DE60230687D1/de not_active Expired - Lifetime
- 2002-11-27 HR HR20040547A patent/HRP20040547A2/xx not_active Application Discontinuation
- 2002-11-27 EP EP05006610A patent/EP1574212A1/en not_active Withdrawn
- 2002-11-27 SI SI200230705T patent/SI1460969T1/sl unknown
- 2002-11-27 WO PCT/US2002/036136 patent/WO2003047504A2/en active Application Filing
- 2002-11-27 JP JP2003548765A patent/JP2005515988A/ja active Pending
- 2002-11-27 DE DE60226494T patent/DE60226494D1/de not_active Expired - Lifetime
- 2002-12-16 TW TW091136262A patent/TWI315987B/zh not_active IP Right Cessation
2005
- 2005-04-07 JP JP2005110874A patent/JP2005247862A/ja active Pending
2008
- 2008-07-03 CY CY20081100699T patent/CY1108174T1/el unknown
- 2008-07-15 AU AU2008203121A patent/AU2008203121A1/en not_active Abandoned
2009
- 2009-03-23 CY CY20091100318T patent/CY1108895T1/el unknown
2010
- 2010-06-27 IL IL206646A patent/IL206646A0/en unknown

Also Published As

Publication number	Publication date
AU2002356928A1 (en)	2003-06-17
WO2003047504A3 (en)	2003-10-16
EP1460969A4 (en)	2005-08-17
KR20050044618A (ko)	2005-05-12
EP1666033B1 (en)	2008-12-31
DK1666033T3 (da)	2009-04-06
DE60226494D1 (de)	2008-06-19
CA2468719C (en)	2011-05-24
MXPA04005112A (es)	2005-04-29
EP1862165A2 (en)	2007-12-05
ATE418972T1 (de)	2009-01-15
US6899888B2 (en)	2005-05-31
EA200400744A1 (ru)	2005-02-24
PT1460969E (pt)	2008-07-01
EP2098247A2 (en)	2009-09-09
EP1460969A2 (en)	2004-09-29
CY1108174T1 (el)	2014-02-12
CA2468719A1 (en)	2003-06-12
AU2008203121A1 (en)	2008-08-07
CN100548283C (zh)	2009-10-14
GEP20094841B (en)	2009-11-25
IL206646A0 (en)	2011-07-31
SI1460969T1 (sl)	2008-10-31
BR0214801A (pt)	2005-01-11
ES2319785T3 (es)	2009-05-12
CY1108895T1 (el)	2014-07-02
PT1666033E (pt)	2009-02-09
WO2003047504A2 (en)	2003-06-12
CN1617691A (zh)	2005-05-18
JP2005515988A (ja)	2005-06-02
EP1666033A1 (en)	2006-06-07
DK1460969T3 (da)	2008-09-01
ATE394099T1 (de)	2008-05-15
ES2305350T3 (es)	2008-11-01
US20030153625A1 (en)	2003-08-14
JP2005247862A (ja)	2005-09-15
TWI315987B (en)	2009-10-21
HK1092066A1 (en)	2007-02-02
CA2537913A1 (en)	2003-06-12
HK1068104A1 (en)	2005-04-22
EP1862165A3 (en)	2008-06-25
EP2098247A3 (en)	2010-05-26
KR100658110B1 (ko)	2006-12-14
DE60230687D1 (de)	2009-02-12
EP1574212A1 (en)	2005-09-14
IL162144A0 (en)	2005-11-20
EP1460969B1 (en)	2008-05-07
AU2002356928B2 (en)	2008-04-17
HRP20040547A2 (en)	2005-08-31
CN1679956A (zh)	2005-10-12
TW200410711A (en)	2004-07-01

Publication	Publication Date	Title
IL162144A0 (en)	2005-11-20	Prevention and treatment of androgen-deprivation induced osteoporosis
EP1446114A4 (en)	2005-05-25	COMPOSITIONS AND METHODS FOR TREATING OSTEOPOROSIS
AU6147401A (en)	2001-11-26	Compositions and methods for the treatment of cancer
AU5160201A (en)	2001-10-30	Compositions comprising natural agents for treatment of cancer
HUP0104688A3 (en)	2004-07-28	Compositions and methods for the prevention or treatment of cancer and bone loss associated with cancer
PL352931A1 (en)	2003-09-22	Compositions and uses of et743 for treating cancer
IL159887A0 (en)	2004-06-20	Combination therapy for the treatment of cancer
EP1379242A4 (en)	2007-10-03	METHOD OF TREATING CANCERS AND APPROPRIATE COMPOSITIONS
MXPA03008582A (es)	2003-12-08	Agentes y metodos para tratamiento de cancer.
IL145397A0 (en)	2002-06-30	Compositions and methods for treatment of cancer
IL151932A0 (en)	2003-04-10	Use of fulvestrant in the treatment of resistant breast cancer
IL124650A0 (en)	1998-12-06	Methods and therapeutic compositions for treating cancer
PL368035A1 (en)	2005-03-21	Compositions and methods for the treatment of cancer
IL161332A0 (en)	2004-09-27	Pacap compositions and methods for tumor imaging and therapy
IL143671A0 (en)	2002-04-21	PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF BREAST CANCER COMPRISING hCG
EP1423118A4 (en)	2006-03-22	METHOD AND COMPOSITION FOR CANCER TREATMENT
AU2002360454A8 (en)	2003-06-10	Methods and compositions for treating cancer
EP1576113A4 (en)	2010-08-18	TUMOR ANTIGENS BFA4 AND BCY1 FOR PREVENTING AND / OR TREATING CANCER
TWI319324B (en)	2010-01-11	The use of anti-estrogens for the prevention and treatment of androgen-deprivation induced osteoporosis, loss of bone mineral density and/or bone fractures in males subjects with prostate cancer
EP1515748A4 (en)	2006-04-12	ANTIESTROGEN AND IMMUNOMODULATOR COMBINATIONS FOR THE TREATMENT OF BREAST CANCER
IL160816A0 (en)	2004-08-31	Compositions and methods for treatment of cancer
SI1531843T1 (sl)	2011-11-30	Postopek za zdravljenje raka materničnega vratu